NCT00255177View on ClinicalTrials.gov

Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

January 31, 2008

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

VGX-410 (Mifepristone)

VGX-410 tablets taken daily or twice daily for 28 days

DRUG

Placebo

Placebo for VGX-410 tablets taken daily or twice daily for 28 days

Trial Locations (4)

19104

University of Pennsylvania, Philadelphia

32809

Orlando Clinical Research Center, Orlando

63104

Saint Louis University, St Louis

06030

University of Connecticut, Farmington

All Listed Sponsors
lead

VGX Pharmaceuticals, LLC

INDUSTRY

NCT00255177 - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients | Biotech Hunter | Biotech Hunter